Connect with us

Medical

Large UAS Labs Clinical Study: Probiotics Shown to be Good for Digestion and IBS

Deborah Killion

Published

on

Large UAS Labs Clinical Study: Probiotics Shown to be Good for Digestion and IBS
- ad -

Some probiotics strains supplements can alleviate irritable bowel syndrome (IBS) symptoms, improving the quality of life, says the sixth largest probiotic-digestive health clinical study conducted by UAS Labs , which used either Bifidobacterium animalis subsp. lactis UABla-12 or Lactobacillus acidophilus DDS-1 on 330 subjects, for 6 weeks.

How Was the Study Conducted?

The study was double-blind, randomized and placebo controlled. It was conducted on 330 adults, at 12 different sites from India. The participants to it were suffering from IBS as per the Rome IV criteria indicated. Three groups of the volunteers were formed: a placebo one, a Lactobacillus acidophilus DDS-1 with 10 billion CFU per day one, and a Bifidobacterium animalis susbsp. lactis UABla-12 with 10 billion CFU per day one. The tests went on for 6 weeks. When compared to those in the placebo group, subjects in the probiotic groups had an improved Abdominal Pain Severity – Numeric Rating Scale (APS – NRS). An amelioration in their OBS Symptom Severity Scale (IBS-SSS) was also recorded. Furthermore, those in the probiotic groups had significantly more normal stools than those in the placebo group. Here’s are the study’s conclusions:

“It is of interest that both probiotic strains, most notably L. acidophilus DDS-1, showed a significant group response as well an individual response to intervention […]. The high responder rates observed herein may also be applicable more generally.”

What Were the Study’s Results?

The results of the study indicated that both these probiotic strains show improvements on the IBS Symptom Severity Scale when compared with the placebo. The symptoms they showed alleviation for are bloating, abdominal pain and bowel habits, all while their quality of life was improved. Here’s what UAS Labs’ Gregory Leyer and Christopher Martoni, together with India’s Vedic Lifesciences’ Shalini Srivastava wrote about the study’s discoveries:

“Both probiotic strains helped improve total symptomology as per validated questionnaire, with changes that could be classified as clinically significant.”

In the meantime, Dr Leyer had this to comment about the science behind DDS-1:

“While the research supporting our DDS-q strain of L. acidophilus is copious, this clinical trial provided the opportunity to growing its portfolio […]. Adding B. lactis as a separate arm allowed us to evaluate two different probiotic genera for optimal performance. We are beyond thrilled with the impact both have shown on digestive health.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

- ad -

Disclaimer: Please understand that any news, guides or reviews found here are not a worthy substitute for medical advice. It is extremely wise to consult with a licensed healthcare professional or physician before adding any new health product or program to your routine. No supplements or services here are intended to diagnose, cure or prevent any disease.

Disclosure: Links located within this website may be affiliate placements where referral rewards will be generated if you make a purchase. This adds no additional cost to you and does not change the outcome of the research or review, but goes back into site upkeep and team sustainability.